The most dramatic example of this is the variable response to BRAF inhibitors across different tumor types, ranging from a high response in BRAF V600E-mutated melanoma to a complete lack of activity of such agents in BRAF V600E-mutated colorectal cancer (62–64). The gene discussed is BRAF; the disease is melanoma.